Format

Send to

Choose Destination
J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S97-107. doi: 10.1016/j.jacc.2009.04.007.

End points and clinical trial design in pulmonary arterial hypertension.

Author information

1
Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan 48109-0273, USA. vmclaugh@med.umich.edu

Abstract

New and emerging therapies might provide benefit in patients with pulmonary arterial hypertension. Their efficacy and safety will be compared with existing combination therapies in randomized clinical trials. Appropriate end points for these trials need to be identified: these will include exercise testing, the composite end point of time to clinical worsening, and hemodynamic markers, including advanced imaging modalities and biomarkers. Quality-of-life questionnaires are useful and important secondary end points; pulmonary arterial hypertension-specific questionnaires are currently being developed. Advantages and disadvantages of various trial designs, including placebo-controlled monotherapy or add-on trials, noninferiority studies, and withdrawal trials are also discussed.

PMID:
19555863
DOI:
10.1016/j.jacc.2009.04.007
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center